How effective is Secukinumab in treating ankylosing spondylitis?

Secukinumab is the first biologic treatment to treat ankylosing spondylitis (AS) by specifically targeting and blocking IL-17A, which is thought to play a role in causing inflammation One of a variety of molecules, ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disease that primarily affects the axial skeleton. Typical symptoms include chronic back pain, stiffness, and progressive loss of spinal mobility. NSAIDs are the first-line recommended drugs for the treatment of active ankylosing spondylitis. The tolerability of secukinumab in patients with ankylosing spondylitis is consistent with that in patients with plaque psoriasis.